Amin T. Re-visiting the patents and access to medicines dichotomy: an evaluation of TRIPS implementation and public health safeguards in developing countries. In The Global Governance of HIV/AIDS. Edward Elgar Publishing; 2013.
Amin T, Kesselheim AS. Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades. Health Affairs (Project Hope). 2012;31(10):2286–94.
Arora A, Branstetter L, Chatterjee C. Strong medicine: patent reform and the emergence of a research-driven pharmaceutical industry in India. NBER Conference on Location of Biopharmaceutical Activity; 2008.
Basheer S. Patent oppositions in India: the ‘efficacy’ of Section 3(d).” Spicy IP. http://spicyipindia.blogspot.com/2009/09/patent-oppositions-in-india-efficacy-of.html 2009.
Basheer S, Reddy P. The “Efficacy” of Indian patent law: ironing out the creases in section 3(d).” SSRN Scholarly Paper ID 1086254. Rochester: Social Science Research Network; 2008.
Basso M. Intervention of health authorities in patent examination: the Brazilian practice of the prior consent. Int J Intellect Prop Manage. 2006;1(1/2):54–74.
Berndt ER, Cockburn IM, Grépin KA. The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications. PharmacoEconomics. 2006;2(24 Suppl):69–86.
Commission on Intellectual Property Rights. Integrating intellectual property rights and development policy. Commission on Intellectual Property Rights; 2002.
Correa CM. Guidelines for the examination of pharmaceutical patents: developing a public health perspective. ICTSD; 2007
Drahos P. ‘Trust me’: patent offices in developing countries. Am J Law Med. 2008;34(2/3):151.
Drahos P. The global governance of knowledge: patent offices and their clients. Cambridge: Cambridge University Press; 2010.
Falvey R, Foster N, Greenaway D. Intellectual property rights and economic growth. Rev Dev Econ. 2006;10(4):700–19.
Falvey R, Foster N, Greenaway D. Trade, imitative ability and intellectual property rights. Rev World Econ. 2009;145(3):373–404.
Farrell J, Merges RP. Incentives to Challenge and Defend Patents: Why Litigation Won’t Reliably Fix Patent Office Errors and Why Administrative Patent Review Might Help. Berkeley Technol Law J. 2004;19(1):943–70.
Gopakumar KM. The Need to Curb Patents on Known Substances. Econ Polit Wkly. 2013;48(32):55–7.
GSK. Evergreening. GlaxoSmithKline Briefings. GlaxoSmithKline; 2007.
Hemphill CS, Sampat BN. When do generics challenge drug patents?”. J Empir Leg Stud. 2011;8(4):613–49.
Hemphill CS, Sampat BN. Evergreening, patent challenges, and effective market life in pharmaceuticals. J Health Econ. 2012;31(2):327–39.
Hemphill CS, Sampat B. Drug patents at the Supreme Court. Science. 2013;339(6126):1386–7.
Howard L. Use of patents in drug lifecycle management. J Gen Med Bus J Gen Med Sect. 2007;4(3):230–6.
Hunt M. Changing patterns of pharmaceutical innovation: a research report. The National Institute for Health Care Management Foundation 2002.
IFPMA. Incremental innovation: adapting to patient needs. International Federation of Pharmaceutical Manufacturers & Associations. http://www.ifpma.org/innovation/ip-rights/incremental-innovation.html 2013.
Ivus O. Do stronger patent rights raise high-tech exports to the developing world? J Int Econ. 2010;81(1):38–47.
Kapczynski A. Harmonization and its discontents: a case study of trips implementation in India’s pharmaceutical sector. California Law Rev. 2009;97:1571–649.
Kapczynski A, Park C, Sampat B. Polymorphs and prodrugs and salts (Oh My!): an empirical analysis of ‘secondary’ pharmaceutical patents. PLoS One. 2012;7(12):e49470.
Kunisawa VYM. Patenting pharmaceutical inventions on second medical uses in Brazil. J World Intellect Prop. 2009;12(4):297–316.
Kyle MK, McGahan AM. Investments in pharmaceuticals before and after TRIPS. Rev Econ Stat. 2012;94(4):1157–72.
La Croix S, Liu M. The effect of GDP growth on pharmaceutical patent protection, 1945–2005. Brussels Econ Rev. 2009;52(3/4):355–75.
Lemley M. Rational Ignorance at the Patent Office. SSRN Scholarly Paper ID 261400. Rochester, NY: Social Science Research Network. http://papers.ssrn.com/abstract=261400. 2001.
Lemley M, Sampat BN. Is the patent office a rubber stamp? Emory Law J. 2008;58:181.
Liu M, La Croix S. A cross-Country index of intellectual property rights in pharmaceutical inventions. Res Policy. 2015;44(1):206–16.
Matthews D, Correa C The doha declaration ten years on and its impact on access to medicines and the right to health. United Nations Development Program; 2011.
Morin J-F, Gold ER. An integrated model of legal transplantation: the diffusion of intellectual property law in developing Countries. Int Stud Q. 2014;58(4):781–92.
MSF. n.d. “Patent opposition database.” Médecins Sans Frontières (MSF) International. http://www.msf.org/article/patent-opposition-database.
Park WG. International patent protection: 1960–2005. Res Policy. 2008;37(4):761–6.
Qian Y. Do national patent laws stimulate domestic innovation in a global patenting environment? a cross-country analysis of pharmaceutical patent protection, 1978–2002. Rev Econ Stat. 2007;89(3):436–53.
Sampat BN, Amin T. How do public health safeguards in indian patent law affect pharmaceutical patenting in practice?” J Health Polit Policy Law. 2013;38(4):735–55.
Scherer FM. The pharmaceutical industry. Handb Health Econ B. 2000;1:1297–336.
Sengupta A. Two decades of struggle. Econ Polit Wkly. 2013;48(32):43–5.
Shadlen KC. The political contradictions of incremental innovation: lessons from pharmaceutical patent examination in Brazil. Polit Soc. 2011;39(2):143–74.
Shadlen KC. The rise and fall of ‘prior consent’ in Brazil. WIPO J. 2012;3(1):103–12.
South Centre. The Doha declaration on TRIPS and public health ten years later: the state of implementationpolicy brief 7, November 2011.” Policy Brief 7; 2011
Sweet CM, Maggio DSE. Do stronger intellectual property rights increase innovation? World Dev. 2015;66:665–77.
UNAIDS. Doha + 10 TRIPS Flexibilities and Access to Antiretroviral Therapy: Lessons from the Past, Opportunities for the Future. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2260_DOHA+10TRIPS_en.pdf. 2011.
Vernaz N, Haller G, Girardin F, Huttner B, Combescure C, Dayer P, et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. PLoS Med. 2013;10(6):e1001460.
WIPO. World intellectual property indicators: 2011 Edition. World Intellectual Property Organization. 2011.